DECISION OF THE EEA JOINT COMMITTEE No 6/2023

of 3 February 2023

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/2324]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

(1) Regulation (EU) 2022/641 of the European Parliament and of the Council of 12 April 2022 amending Regulation (EU) No 536/2014 as regards a derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom in respect of Northern Ireland and in Cyprus, Ireland and Malta ( 1 ) is to be incorporated into the EEA Agreement.

(2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following is added in point 18 (Regulation (EU) No 536/2014 of the European Parliament and of the Council) of Chapter XIII of Annex II to the EEA Agreement:

‘, as amended by:

— 32022 R 0641 : Regulation (EU) 2022/641 of the European Parliament and of the Council of 12 April 2022 ( OJ L 118, 20.4.2022, p. 1 ).’

Article 2

The text of Regulation (EU) 2022/641 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union , shall be authentic.

Article 3

This Decision shall enter into force on 4 February 2023, provided that all the notifications under Article 103(1) of the EEA Agreement have been made ( *1 ) .

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union .

Done at Brussels, 3 February 2023.

For the EEA Joint Committee

The President

Nicolas VON LINGEN

( 1 ) OJ L 118, 20.4.2022, p. 1 .

( *1 ) No constitutional requirements indicated.

ELI: http://data.europa.eu/eli/dec/2023/2324/oj

ISSN 1977-0677 (electronic edition)